Novo Nordisk Launches Diabetes Trial in Late-Stage Journey for Semaglutide

AI generated by AppliedXL
October 31, 2023
AI-generated image featuring Novo Nodisk's logo.
AI-generated image featuring Novo Nodisk's logo.

Novo Nordisk Registers New Phase 3 Diabetes Study

  • Danish pharmaceutical leader, Novo Nordisk A/S, has freshly initiated a large-scale international trial examining Semaglutide Tablets in comparison with Empagliflozin or Metformin for individuals grappling with Type 2 Diabetes.
  • The investigation seeks to regulate blood sugar and weight in those newly diagnosed, aiming high with an enrollment target of 912 across 102 centers.
  • The research journey is mapped out for about 111 weeks, eyeing a finish line of January 24, 2025.

Pioneering Pursuits with Semaglutide

  • They are not stopping there; Novo Nordisk has embarked on five clinical endeavors since 2014, focusing on examining Semaglutide's prowess in treating Type 2 Diabetes. These span from mid to late-stage trials, targeting a cumulative 4468 patients across a vast 660 facilities globally, with wrap-up dates stretching to 2025.

Diverse Drug Pipeline

  • The company is putting Somapacitan, a budding growth hormone solution, under the lens with conclusions due by August 2024.
  • Their scientific appetite also extends to Etavopivat, aimed at ailments like Sickle Cell Disease and Anemia in MDS patients, with research activities expected to conclude by December 2025.
  • Novo Nordisk's quest to combat bleeding episodes in haemophilia A patients has led to Mim8, with the trials eyeing completion by February 2025.

Battle for Dominance in Diabetes and Obesity Management

  • American pharmaceutical powerhouse, Eli Lilly, is currently scrutinizing orforglipron across eight studies spanning initial to late-stage trials, with the curtains set to drop by June 13, 2025.
  • South Korean pharma player, Daewoong Pharmaceutical Co. LTD., is evaluating DWP16001's potential for Type 2 diabetes, aiming for a completion date of April 30, 2024.
  • Meanwhile, Chinese medicine mogul, Jiangsu HengRui Medicine Co., Ltd., delves into INS068's promise for those whose Type 2 diabetes remains uncontrolled, with investigations set between 2022 to 2025.

Sources:, PubMed, Press Releases, and AppliedXL. This report is generated algorithmically and may not cover all ongoing industry-sponsored trials. AppliedXL implements rigorous AI vetting processes but cannot guarantee the completeness of all insights. 

Want real-time insights?
Request Free Trial